---
figid: PMC8880564__pharmaceuticals-15-00246-g001
figtitle: Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor
  Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition
organisms:
- NA
pmcid: PMC8880564
filename: pharmaceuticals-15-00246-g001.jpg
figlink: /pmc/articles/PMC8880564/figure/pharmaceuticals-15-00246-f001/
number: F1
caption: 'Basic pharmacophoric features of sorafenib (PDB ID: 3WZE).'
papertitle: Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor
  Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.
reftext: Mater H. Mahnashi, et al. Pharmaceuticals (Basel). 2022 Feb;15(2):246.
year: '2022'
doi: 10.3390/ph15020246
journal_title: Pharmaceuticals
journal_nlm_ta: Pharmaceuticals (Basel)
publisher_name: MDPI
keywords: pyrazolo[3,4-d]pyrimidines | furoxan | VEGFR-2 | DAF-FM DA | MAPK | metastasis
  | apoptosis
automl_pathway: 0.6299121
figid_alias: PMC8880564__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
redirect_from: /figures/PMC8880564__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8880564__pharmaceuticals-15-00246-g001.html
  '@type': Dataset
  description: 'Basic pharmacophoric features of sorafenib (PDB ID: 3WZE).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Cys
  - mmy
  - Csp
  - fl
  - ci
---
